Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03482245 · ClinicalTrials.gov registry record · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
A NA study of Pneumonia and Necrotizing Soft Tissue Infection, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- NA
- Development phase
- 144
- Enrollment target
- 1
- Study location
NCT03482245: Recruiting NA study of Pneumonia and Necrotizing Soft Tissue Infection, sponsored by Washington University School of Medicine.
NCT03482245 is a NA study of Pneumonia and Necrotizing Soft Tissue Infection that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 144 participants, below the 4,516-participant average among 47 other Pneumonia trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03482245, a NA study of Pneumonia and Necrotizing Soft Tissue Infection, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- NA
- Development phase
- 144 participants
- Enrollment target
- 1
- Study location
Study Summary
Our data suggest that modulating the characteristics of light carries the potential to modify the host response to injury and critical illness and thus, improve outcome. The ability to modify the host response to the stress of major operations and sepsis carries immense potential to improve patient care. The primary purpose of this study is to determine if exposure to bright blue (442nm) enriched light, by comparison to ambient white fluorescent light, reduces the inflammatory response or organ dysfunction in patients undergoing 1) medical treatment for pneumonia, 2) a 2-stage arthroplasty for surgical management of a septic joint, 3) surgery for a necrotizing soft tissue infection (NSTI), and 4) surgery for an intraabdominal infection (e.g., diverticulitis). We will expose participants to one of two (2) lighting conditions: 1) high illuminance (\~1700 lux,), blue (442nm) spectrum enriched light and 2) ambient white fluorescent light that provides the standard environmental lighting (\~300-400 lux, no predominant spectrum) of the hospital. Both cohorts will be exposed to a 12 hours:12 hours light:dark cycle photoperiod. Those subjects assigned to blue light will be asked to shine this small portable blue enriched light on themselves from 0800 to 2000 for 3 days. At the transition from light to dark, the blue-enriched light is turned off, and additional blue wavelength light removed with an amber filter. Thus, the total period of intervention is 72 hours. The outcome of interest is change in the inflammatory response after surgery for appendicitis or diverticulitis as measured by the following parameters: white blood cell count, heart rate, the development of abdominal abscess, serum cytokine concentrations. The outcome of interest is change in the inflammatory response during pneumonia as measured by the following parameters: white blood cell count, heart rate, and serum cytokine concentrations.
Primary Outcome
quantification of the change in bacterial colony forming units (CFU) in BAL fluid
Conditions Studied
Interventions
- OTHER Blue Light
Study Locations (1)
Missouri
- Barnes Jewish Hospital - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2024-10-29 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What NCT03482245 shows while recruiting
NCT03482245 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, below the 4,516-participant average among 47 other Pneumonia trials with a reported enrollment target (97% lower).
The record links to 4 conditions, with Pneumonia appearing as the primary indexed condition, and to 1 intervention - of which Blue Light is the first listed.
NCT03482245 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT03482245 about?
NCT03482245 is a clinical study titled "The Role of Circadian Clock Proteins in Innate and Adaptive Immunity". Our data suggest that modulating the characteristics of light carries the potential to modify the host response to injury and critical illness and thus, improve outcome. The ability to modify the host response to the stress of major operations and sepsis carries immense potential to improve patient ...
What is the current status of trial NCT03482245?
This trial is currently recruiting. It is a NA study. The enrollment target is 144 participants. The study started on 2024-10-29. Estimated completion is 2026-12-31.
What conditions does trial NCT03482245 study?
This clinical trial studies the following conditions: Pneumonia, Necrotizing Soft Tissue Infection, Intraabdominal Infections, Infection Joint.
What interventions are being tested in trial NCT03482245?
The interventions under investigation include: Blue Light (OTHER).
Who is sponsoring clinical trial NCT03482245?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03482245 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pneumonia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03482245's enrollment target sits among peer trials
144 27th of 47 higher than 21 of 47 other Pneumonia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pneumonia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reducing Overuse of Antibiotics With Decision Support
RECRUITING · NA
-
Extending Dental Care to Nursing Home Residents to Reduce Mouth Infections and Incidence of Pneumonia and Improve Diabetic Glucose Control
RECRUITING · NA
-
Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU
RECRUITING · NA
-
Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial
RECRUITING · NA
-
How OMT Benefits Newly Diagnosed Patients With Respiratory Illness When Given Alongside Other Standard Care.
RECRUITING · NA
-
PICNIC Study - PatIent Centered aNtIbiotic Courses in Children With Medical Complexity
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
- NCT04215809 · 144 participants · Phase 1
Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI